30 articles for WH Miller
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery of an imidazopyridine-containing 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonist with efficacy in a restenosis model.
Smithkline Beecham Pharmaceuticals
Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2.
TBA
Acylprolinamides: a new class of peptide deformylase inhibitors with in vivo antibacterial activity.
Glaxosmithkline
Novel amino-piperidines as potent antibacterials targeting bacterial type IIA topoisomerases.
Glaxosmithkline
Structure-based design of potent and selective 3-phosphoinositide-dependent kinase-1 (PDK1) inhibitors.
Glaxosmithkline
Discovery of a new series of Aurora inhibitors through truncation of GSK1070916.
Glaxosmithkline
Structure-activity relationships in 3-oxo-1,4-benzodiazepine-2-acetic acid GPIIb/IIIa antagonists. The 2-benzazepine series
TBA
A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC.
Johns Hopkins University
Phenylbutyrates as potent, orally bioavailable vitronectin receptor (integrin alphavbeta3) antagonists.
Glaxosmithkline
Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic.
Smithkline Beecham Pharmaceuticals
Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model.
Smithkline Beecham Pharmaceuticals
Orally bioavailable nonpeptide vitronectin receptor antagonists containing 2-aminopyridine arginine mimetics.
Smithkline Beecham Pharmaceuticals
Conformational preferences in a benzodiazepine series of potent nonpeptide fibrinogen receptor antagonists.
Smithkline Beecham Pharmaceuticals
Benzimidazole derivatives as arginine mimetics in 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonists.
Smithkline Beecham Pharmaceuticals
Discovery of potent nonpeptide vitronectin receptor (alpha v beta 3) antagonists.
Smithkline Beecham Pharmaceuticals
Potent, selective, orally active 3-oxo-1,4-benzodiazepine GPIIb/IIIa integrin antagonists.
Smithkline Beecham Pharmaceuticals
Potent non-peptide fibrinogen receptor antagonists which present an alternative pharmacophore.
Smithkline Beecham Pharmaceuticals
Combining symmetry elements results in potent naphthyridinone (NTD) HIV-1 integrase inhibitors.
Glaxosmithkline Research & Development
The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral.
Glaxosmithkline
Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Array Biopharma
Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
Array Biopharma
Aniline derivative, pharmaceutical composition containing same, and use thereof
Kissei Pharmaceutical
Guanidine substituted tetrahydroisoquinoline compounds as factor XIa inhibitors
Bristol-Myers Squibb
Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use
Amgen
2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.
Glaxosmithkline
Nonpeptide cyclic cyanoguanidines as HIV-1 protease inhibitors: synthesis, structure-activity relationships, and X-ray crystal structure studies.
Dupont Pharmaceuticals